Seqens Seqens

X

Find Drugs in Development News & Deals for DSSTox_CID_3195

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
132
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET;ORAL - 100MG
  • TABLET;ORAL - 150MG
  • TABLET;ORAL - 200MG
  • TABLET;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET;ORAL - 25MG
  • TABLET;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Details:

Under the partnership OWP will launch and commercialize its oral liquid formulations for neuroscience disorders. OWP has also received IND for Lamotrigine in multiple therapies for epilepsy, schizophrenia, bipolar disorder, major depressive, anxiety disorder, and migraines.


Lead Product(s): Lamotrigine

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Eversana

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 05, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Aquistion covers the lead products include the branded generics Cital® and Lamotrix® (lamotrigine), both relevant brands in their respective markets. With branded generics commanding the dominant share of market, Poland has the highest penetration of generics in Europe.


Lead Product(s): Lamotrigine

Therapeutic Area: Neurology Product Name: Lamotrix

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Neuraxpharm

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition February 25, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY